These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27803966)

  • 1. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer.
    Sui W; Matulay JT; Onyeji IC; Theofanides MC; James MB; RoyChoudhury A; Wenske S; DeCastro GJ
    World J Urol; 2017 Jul; 35(7):1055-1061. PubMed ID: 27803966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
    Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
    J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns.
    Patel SG; Stimson CJ; Zaid HB; Resnick MJ; Cookson MS; Barocas DA; Chang SS
    J Urol; 2014 Feb; 191(2):329-34. PubMed ID: 24036236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
    Wright JL; Black PC; Brown GA; Porter MP; Kamat AM; Dinney CP; Lin DW
    J Urol; 2007 Dec; 178(6):2302-6; discussion 2307. PubMed ID: 17936803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.
    Fischer-Valuck BW; Rao YJ; Henke LE; Rudra S; Hui C; Baumann BC; Gay HA; Michalski JM
    Eur Urol Focus; 2018 Dec; 4(6):900-906. PubMed ID: 28919521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.
    Moschini M; Soria F; Klatte T; Wirth GJ; Özsoy M; Gust K; Briganti A; Roupret M; Susani M; Haitel A; Shariat SF
    Clin Genitourin Cancer; 2017 Apr; 15(2):e267-e273. PubMed ID: 27530435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
    Duivenvoorden WC; Daneshmand S; Canter D; Lotan Y; Black PC; Abdi H; van Rhijn BW; Fransen van de Putte EE; Zareba P; Koskinen I; Kassouf W; Traboulsi SL; Kukreja JE; Boström PJ; Shayegan B; Pinthus JH
    J Urol; 2016 Dec; 196(6):1627-1633. PubMed ID: 27312316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive non-urachal adenocarcinoma of the bladder: analysis of the National Cancer Database.
    Davaro F; Schaefer J; May A; Raza J; Siddiqui S; Hamilton Z
    World J Urol; 2019 Mar; 37(3):497-505. PubMed ID: 30030660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcomatoid Carcinoma of the Urinary Bladder.
    Malla M; Wang JF; Trepeta R; Feng A; Wang J
    Clin Genitourin Cancer; 2016 Oct; 14(5):366-372. PubMed ID: 27050715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
    Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
    Zargar H; Zargar-Shoshtari K; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black P;
    J Urol; 2016 Apr; 195(4 Pt 1):886-93. PubMed ID: 26521718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.
    Fisher MD; Shenolikar R; Miller PJ; Fenton M; Walker MS
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1171-e1179. PubMed ID: 30206026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
    von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD
    Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
    Zargar-Shoshtari K; Kongnyuy M; Sharma P; Fishman MN; Gilbert SM; Poch MA; Pow-Sang JM; Spiess PE; Zhang J; Sexton WJ
    World J Urol; 2016 Nov; 34(11):1567-1573. PubMed ID: 27072536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.
    Lopez-Beltran A; Pacelli A; Rothenberg HJ; Wollan PC; Zincke H; Blute ML; Bostwick DG
    J Urol; 1998 May; 159(5):1497-503. PubMed ID: 9554341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.